CytoMed Therapeutics Ltd SEC Filings

CytoMed Therapeutics Limited reports that its wholly owned subsidiary Advance Cancer Centre Pte. Ltd., established in 2020, has been renamed CytoMed International Pte. Ltd., effective May 6, 2026. The new name is meant to reflect a stronger push into international markets.

The company plans to expand its footprint through overseas joint ventures, international medical tourism initiatives, and appointment of overseas representatives, with an initial focus on Asia, especially China, where its allogeneic gamma delta T cell technology is drawing partner interest following China’s Directive 818. The subsidiary currently holds a 19.0% equity interest in a licensed clinic in Malaysia and may increase this stake in the future. The name change does not alter the subsidiary’s legal entity, ownership structure, or contracts, and CytoMed intends to use internal resources to fund this international platform.

CytoMed Therapeutics Limited is convening its Annual General Meeting on May 22, 2026 in Singapore and asking shareholders to vote on ten ordinary resolutions. Routine items include adopting the 2025 Singapore statutory and Form 20-F financial statements, re-electing two directors, ratifying WWC, P.C. and KE Trust PAC as auditors for 2026, and approving directors’ fees of US$70,000.

Shareholders are also asked to approve a waiver from the Singapore Code on Take-overs and Mergers, relying instead on U.S. and Nasdaq rules, and to authorize the board to issue new ordinary shares and related instruments, within applicable laws and Nasdaq Listing Rules, until the next AGM. Voting is restricted to holders of ordinary shares on April 10, 2026 who remain shareholders through May 19, 2026, with each of the 11,832,835 outstanding shares entitled to one vote.

CytoMed Therapeutics reported full-year 2025 revenue and other operating income of US$780,857, up from US$663,786 in 2024, but its audited net loss widened to US$3.11 million from US$1.96 million. Excluding non-cash share-based payments and NASDAQ listing-related costs, the loss would have been US$2.12 million.

Cash and bank balances fell to US$1.63 million as of December 31, 2025, from US$3.87 million a year earlier. Research expenses rose to US$1.72 million, driven by higher consumables, employee benefits and clinical trial spending. Employee benefits expanded to US$723,667, reflecting the first post-IPO share awards.

The company highlighted progress in its allogeneic gamma delta T cell programs. Its ANGELICA CAR-T Phase I trial in Singapore has treated six patients and is moving to the highest dose level, with completion targeted this year. CytoMed also signed an MOU for a Phase I trial in Malaysia using unmodified γδ T cells, co-authored preclinical AML research with MD Anderson Cancer Center, and acquired Malaysian cord blood banking assets to support future cell-based therapies.

CytoMed Therapeutics Limited files its annual report as a clinical-stage biopharmaceutical company focused on novel cell therapies and still operating at a loss.

The Singapore-based Nasdaq-listed issuer had 11,828,435 ordinary shares outstanding as of December 31, 2025 and no products approved for commercial sale. It reports accumulated losses of S$14.85 million as of December 31, 2024 and S$18.83 million as of December 31, 2025, with cash and bank balances declining from S$4.97 million to S$2.10 million over the same dates. Management highlights substantial doubt about its ability to continue as a going concern without additional funding. Research expenses were S$1.91 million in 2024 and S$2.22 million in 2025, reflecting continued investment in a pipeline that includes CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC and CTM-NK. CytoMed previously raised approximately S$10.31 million (U.S.$7.81 million) in net proceeds from its April 18, 2023 initial public offering and established an at-the-market program on August 18, 2025 to sell up to U.S.$4,304,945 of ordinary shares to support ongoing development and operations.

A GDTC shareholder filed a notice of proposed sale of 117,337 ordinary shares on NASDAQ through Bank of Singapore, with an approximate sale date of February 12, 2026. The filing notes that there were 11,733,712 ordinary shares outstanding at the time.

The seller previously disposed of ordinary shares over the past three months in three transactions, including 22,950 shares for gross proceeds of $43,889.34, 12,005 shares for $19,659.86, and 8,245 shares for $12,908.25. The shares being sold were originally acquired by share subscription from the issuer in April 2021 and paid for in cash.

CytoMed Therapeutics Limited filed a report describing a public statement it issued to counter inaccurate claims about its research programs, clinical progress, and operations. The company explains that its work centers on CAR γδ T cell and iPSC-derived γδ NKT cell immunotherapies for cancer.

CytoMed states that its lead CAR γδ T cell program has regulatory approval for a first-in-human clinical trial that is ongoing at National University Hospital in Singapore. Other iPSC-derived γδ NKT cell candidates remain in preclinical development, and the company emphasizes that none of its therapies are approved for commercial use.

The company reiterates its focus on regulatory compliance, scientific rigor, transparent disclosure, and indicates it may take action against false or misleading information that could harm its reputation or stakeholders.

CytoMed Therapeutics Limited, a Singapore-based clinical stage cell therapy company, provided a new year update on its pipeline, funding and shareholder engagement. The company is advancing donor-derived gamma delta T cell and Natural Killer cell immunotherapies, including support from Enterprise Singapore for its Natural Killer cell work through subsidiary LongevityBank. Management believes it has enough resources to fund activities for at least a year and is exploring licensing, real estate asset monetisation and strategic partnerships to support the business with less dilution.

CytoMed highlighted a Memorandum of Understanding with Universiti Malaya to run a first-in-human Phase I trial of its allogeneic unmodified gamma delta T cells in no-option cancer patients in Malaysia, targeting an Investigational New Drug submission before June. This complements an ongoing Phase I CAR-T trial in Singapore, where six patients have been treated. The company also cited a recent co-authored preclinical publication with MD Anderson Cancer Center on acute myeloid leukemia and noted that its chairman intends to increase his shareholding. CytoMed is seeking shareholder feedback on a proposed scheme allowing shareholders, subject to medical approval and local rules, to use their shareholdings to access its donor-derived allogeneic unmodified gamma delta T cell therapy.

CytoMed Therapeutics Limited reported that it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia. The parties plan to explore a multi-site, first-in-human Phase I clinical trial of CytoMed’s patented donor-derived gamma delta T cell product candidate.

The proposed trial would focus on cancer patients who have exhausted standard treatment options and would evaluate both the safety and efficacy of using gamma delta T cells sourced from healthy donors. This represents an early clinical step for CytoMed’s off-the-shelf allogeneic cell therapy approach in Malaysia.

CytoMed Therapeutics Limited reported that it has completed the acquisition of synergistic assets from TC BioPharm Limited. These T cell technology assets are intended to be enhanced and re-purposed to treat cancers in China and India, signaling a focus on cell-based cancer therapies in large Asian markets. The announcement was made through a press release dated November 18, 2025, which is attached as an exhibit to this Form 6-K.